Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) EBITDA Margin: 2010-2025

Historic EBITDA Margin for Northwest Biotherapeutics (NWBO) over the last 16 years, with Sep 2025 value amounting to -13,275.00%.

  • Northwest Biotherapeutics' EBITDA Margin fell 718004.00% to -13,275.00% in Q3 2025 from the same period last year, while for Sep 2025 it was -9,862.54%, marking a year-over-year decrease of 526335.00%. This contributed to the annual value of -6,055.35% for FY2024, which is 264014.00% down from last year.
  • According to the latest figures from Q3 2025, Northwest Biotherapeutics' EBITDA Margin is -13,275.00%, which was up 9.36% from -14,645.80% recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' EBITDA Margin registered a high of 925.93% during Q4 2021, and its lowest value of -14,645.80% during Q2 2025.
  • In the last 3 years, Northwest Biotherapeutics' EBITDA Margin had a median value of -6,094.96% in 2024 and averaged -6,884.74%.
  • Per our database at Business Quant, Northwest Biotherapeutics' EBITDA Margin spiked by 37,381,755bps in 2021 and then plummeted by 1,107,012bps in 2025.
  • Northwest Biotherapeutics' EBITDA Margin (Quarterly) stood at 925.93% in 2021, then tumbled by 397,082bps to -3,044.89% in 2022, then tumbled by 35,781bps to -3,402.70% in 2023, then slumped by 760,336bps to -11,006.06% in 2024, then slumped by 718,004bps to -13,275.00% in 2025.
  • Its last three reported values are -13,275.00% in Q3 2025, -14,645.80% for Q2 2025, and -5,667.20% during Q1 2025.